Vardenafil (Greater Than 2.5 mg)/Selected Protease Inhibitors Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Protease inhibitors may slow down how quickly your liver processes vardenafil.
What might happen:
The amount of vardenafil in your blood may increase and cause harmful effects.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) if you experience a painful or prolonged erection, changes in vision, or dizziness. Your doctor may want to change your dose of vardenafil.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Levitra (vardenafil hydrochloride) Canadian prescribing information. Bayer, Inc. October 24, 2006.
- 2.Levitra (vardenafil hydrochloride trihydrate) UK summary of product characteristics. Bayer plc December 20, 2006.
- 3.Levitra (vardenafil hydrochloride) US prescribing information. Bayer Pharmaceuticals Corporation March, 2023.
- 4.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. September, 2016.
- 5.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories December, 2019.
- 6.Prezista (darunavir) US prescribing information. Janssen Therapeutics March, 2023.
- 7.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline March, 2019.
- 8.Viracept (nelfinavir mesylate) US prescribing information. Agouron Pharmaceuticals, Inc. September, 2016.
- 9.Fortovase (saquinavir) US prescribing information. Roche Laboratories, Inc. December, 2004.
- 10.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. March, 2019.
- 11.Paxlovid (nirmatrelvir tablets and ritonavir tablets) US prescribing information. Pfizer Inc. May, 2023.
- 12.Paxlovid (nirmatrelvir tablets and ritonavir tablets) Canadian Product Monograph. Pfizer Canada ULC October, 2023.
- 13.Viekira Pak (ombitasvir, paritaprevir, and ritonavir; dasabuvir) US prescribing information. AbbVie Inc. December, 2019.
- 14.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. June, 2020.
- 15.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents Living with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats -new-guidelines June 13, 2021.
- 16.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.